Study: NCT01093794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 500 mg metformin
Description: Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 500 mg metformin
Description: Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 500 mg metformin
Description: Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 500 mg metformin
Description: Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/500 mg tablet
Description: Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/500 mg tablet
Description: Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/500 mg tablet
Description: Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/500 mg tablet
Description: Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 850 mg metformin
Description: Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 850 mg metformin
Description: Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 850 mg metformin
Description: Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Co-administration of 50 mg sitagliptin and 850 mg metformin
Description: Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/850 mg tablet
Description: Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/850 mg tablet
Description: Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/850 mg tablet
Description: Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin/metformin 50 mg/850 mg tablet
Description: Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.